Characteristics of older patients initiating induction chemotherapy for AML (N = 74)
| Characteristics . | Median (25th, 75th) or % . |
|---|---|
| Demographics | |
| Age (y) | 68.8 (65.8,74.3) |
| 60-69 y | 55.4 |
| 70-79 y | 33.8 |
| ≥80 y | 10.8 |
| Gender (male) | 54.1 |
| Race (white) | 96.0 |
| Education level* | |
| <High school | 25.0 |
| High school | 23.6 |
| College/above | 51.4 |
| Clinical | |
| Hemoglobin (g/dL) | 9.4 (8.5, 10.2) |
| LDH (U/L) | 225.5 (180.0, 357.0) |
| White cell count (×103/mm3) | 3.3 (1.7, 16.9) |
| Creatinine (mg/dL) | 1.0 (0.8, 1.2) |
| Body mass index | 27.9 (24.9, 31.9) |
| ECOG score (≤1)† | 78.1 |
| Prior MDS | 28.4 |
| Cytogenetic risk group‡ | |
| Favorable | 4.1 |
| Intermediate | 64.4 |
| Poor | 31.5 |
| Coronary artery disease | 17.6 |
| Chronic obstructive pulmonary disease | 13.5 |
| Diabetes mellitus | 21.6 |
| Congestive heart failure | 4.1 |
| Treatment§ | |
| Anthracycline+cytarabine | 54.1 |
| Anthracycline+cytarabine+bortezomib | 17.6 |
| Anthracycline+cytarabine+etoposide | 16.2 |
| Cytarabine+amonafide | 9.5 |
| Other | 2.6 |
| Characteristics . | Median (25th, 75th) or % . |
|---|---|
| Demographics | |
| Age (y) | 68.8 (65.8,74.3) |
| 60-69 y | 55.4 |
| 70-79 y | 33.8 |
| ≥80 y | 10.8 |
| Gender (male) | 54.1 |
| Race (white) | 96.0 |
| Education level* | |
| <High school | 25.0 |
| High school | 23.6 |
| College/above | 51.4 |
| Clinical | |
| Hemoglobin (g/dL) | 9.4 (8.5, 10.2) |
| LDH (U/L) | 225.5 (180.0, 357.0) |
| White cell count (×103/mm3) | 3.3 (1.7, 16.9) |
| Creatinine (mg/dL) | 1.0 (0.8, 1.2) |
| Body mass index | 27.9 (24.9, 31.9) |
| ECOG score (≤1)† | 78.1 |
| Prior MDS | 28.4 |
| Cytogenetic risk group‡ | |
| Favorable | 4.1 |
| Intermediate | 64.4 |
| Poor | 31.5 |
| Coronary artery disease | 17.6 |
| Chronic obstructive pulmonary disease | 13.5 |
| Diabetes mellitus | 21.6 |
| Congestive heart failure | 4.1 |
| Treatment§ | |
| Anthracycline+cytarabine | 54.1 |
| Anthracycline+cytarabine+bortezomib | 17.6 |
| Anthracycline+cytarabine+etoposide | 16.2 |
| Cytarabine+amonafide | 9.5 |
| Other | 2.6 |
LDH, lactate dehydrogenase.
Education level was unavailable for one subject.
ECOG score was unavailable for two subjects.
Cytogenetic test results were unavailable for one subject.
Anthracycline dosing: daunorubicin 60 mg/m2 (61%), 45 mg/m2 (13%); idarubicin 12 mg/m2 (24%), 20 mg/m2 (2%); cytarabine dosing 100 mg/m2 (77%), 200 mg/m2 (23%).